CathWorks Adds Vice President of Global Marketing to Leadership Team

CathWorks Adds Vice President of Global Marketing to Leadership Team

KFAR-SABA, ISRAEL and ALISO VIEJO, CA (February 25, 2019) — CathWorks announced that Ramin Mousavi has joined CathWorks as Vice President of Global Marketing & Strategy. Mr. Mousavi, an experienced cardiovascular marketer, will take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets.

Mr. Mousavi has over 15 years of global marketing, strategy, product development and general management expertise and is widely recognized for leading one of the most successful cardiovascular device launches of the past decade. Prior to joining CathWorks, Ramin was the head of marketing for Transcatheter Heart Valves in the U.S. at Edwards Lifesciences. Ramin earned B.S. degrees in both computer- and electrical engineering from UC, Irvine. He also earned an M.B.A. from UC, Irvine and received a Healthcare Executive Leadership certificate for Business Innovation in Global Healthcare from Harvard Business School.

Jim Corbett, CathWorks CEO, said of Ramin’s appointment, “I could not be more excited to have Ramin join our leadership team. His analytical and strategic thinking combined with his experience in launching transformational and innovative technology utilizing advanced digital platforms to raise awareness and increase adoption, will be very beneficial as we launch and grow the adoption of the CathWorks FFRangio System in the United States and globally. The CathWorks System represents a tremendous opportunity for interventional cardiologists to improve the quality of care and lower costs in the treatment of multivessel coronary artery disease.”

Mr. Mousavi said, “I am excited to join CathWorks and I know that physicians and patients will greatly benefit from having an objective, non-invasive platform to routinely support PCI (percutaneous coronary intervention) decision-making during the coronary angiogram. Our goal is to ensure that the CathWorks FFRangio system is clinically and economically beneficial for interventional cardiologists, their patients, and the healthcare system overall.”

The CathWorks FFRangio System quickly and precisely delivers the objective FFR guidance needed to optimize PCI therapy decisions for every patient. It is non-invasive and performed intra-procedurally during coronary angiography without adding additional clinical risk or per-procedure costs. The company received U.S. FDA 510(k) clearance for the CathWorks FFRangio Coronary Vascular Physiologic Simulation Software on December 19, 2018.

CathWorks Announces Completion Of $30 Million Financing

Deerfield Management Leads Series C Financing

KFAR-SABA, ISRAEL and ALISO VIEJO, CA (February 4, 2019) — CathWorks announced the completion of a $30 million Series C financing round led by Deerfield Management.

Jim Corbett, CathWorks CEO stated, “We are delighted to have such a notable investor leading this round and for the continued full participation of our existing syndicate of investors. Our company was fortunate to have tremendous excitement around the CathWorks FFRangio™ System following release of the FAST-FFR clinical study results. This funding, coupled with our recent FDA 510(k) clearance, paves the way for acceleration of our clinical and commercial activities in the United States.”

Deerfield Management Principal, Andrew ElBardissi, MD added, “The CathWorks FFRangio platform technology has the potential to become standard of care in PCI [percutaneous coronary intervention] and other interventions where physiologic assessment is critical to determining which patients would benefit from revascularization. We believe there is tremendous clinical and economic potential for all stakeholders, including clinicians, patients, and payors.”

The CathWorks System received United States Food & Drug Administration 510(k) clearance on December 19, 2018. The predicate used for demonstrating substantial equivalence was conventional invasive FFR as demonstrated during the FAST-FFR clinical study. The CathWorks FFRangio System quickly and precisely delivers the objective FFR guidance needed to optimize PCI therapy decisions for every patient across the full coronary tree. It is non-invasive and performed intra-procedurally during coronary angiography without adding additional clinical risk or perprocedure costs.

CathWorks co-founder, Guy Lavi commented, “We are excited for the investment to support FFRangio market entry and continue with technical and clinical acceleration. As always, we want to thank our clinical development partners in Israel, the United States, and Europe for enabling us to reach this exciting milestone.”

Learn how the CathWorks FFRangio System can impact your practice.

*Required

expand_lessBack to top of page

We use cookies to enhance your experience. By continuing to visit this site, you agree to our use of cookies. Terms and Conditions

Accept